Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.
Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
